[Clinical drug trials in Germany--an assessment of current status from the viewpoint of industry].
Drug development today is a highly professional and costly affair, whereby quality and speed are decisive competitive factors in a global setting. Germany is in the process of losing its attractiveness for clinical drug research as evidenced by a significant decrease in funding of clinical drug research which at the moment amounts to about 1.5 billion DM/year. This decrease is due to an adverse environment created by a certain anxiety in public opinion regarding technological advances, an overburden of regulations, lack of an infrastructure in hospitals to work according to GCP and a regulatory agency which has to compete with momentarily more effective agencies in Europe (UK, France). A joint effort between industry and the medical profession is called for to change this situation for the better.
Baumbauer
E
E
Verband Forschender Arzneimittelhersteller e.V. (VFA), Bonn.
D002986:Clinical Trials as Topic / Q000191:economics*; D003362:Cost-Benefit Analysis; D004345:Drug Industry / Q000191:economics*; D015507:Drugs, Investigational / Q000191:economics; D005858:Germany; D006801:Humans
D015507:Drugs, Investigational
Klinische Arzneimittelforschung in Deutschland--Eine Standortbestimmung aus Sicht der Industrie.